 |
인쇄하기
취소
|
KFDA okays phase 1 study of functional combination drug
Hanall Pharm said on December 23 its has received approval from the Korea Food and Drug Administration to conduct phase 1 clinical trial of a combination drug (amlodipine plus atorvastatin) for the treatment of hypertension and hyperlipidemia.
Hanall officials said the approval comes after successful completion of preclinical trials on HL-037, chrono-xenoiotics therapy based formulation.
...
Hanall officials said the approval comes after successful completion of preclinical trials on HL-037, chrono-xenoiotics therapy based formulation.
...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.